|Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters|
L Engell-Noerregaard, TH Hansen, MH Andersen, P thor Straten, ...
Cancer immunology, immunotherapy 58 (1), 1, 2009
|Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen|
R Andersen, M Donia, E Ellebaek, TH Borch, P Kongsted, TZ Iversen, ...
Clinical Cancer Research 22 (15), 3734-3745, 2016
|Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: a randomized phase II study|
P Kongsted, TH Borch, E Ellebaek, TZ Iversen, R Andersen, ÷ Met, ...
Cytotherapy 19 (4), 500-513, 2017
|Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies|
TH Borch, M Donia, MH Andersen, IM Svane
Drug discovery today 20 (9), 1127-1134, 2015
|PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine|
S Munir Ahmad, E Martinenaite, M Hansen, N Junker, TH Borch, ÷ Met, ...
Oncoimmunology 5 (8), e1202391, 2016
|mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma|
TH Borch, L Engell-Noerregaard, T Zeeberg Iversen, E Ellebaek, ÷ Met, ...
Oncoimmunology 5 (9), e1207842, 2016
|PD-L1-specific T cells|
SM Ahmad, TH Borch, M Hansen, MH Andersen
Cancer Immunology, Immunotherapy 65 (7), 797-804, 2016
|Influence of metronomic cyclophosphamide and interleukin-2 alone or combined on blood regulatory T-cells in patients with advanced malignant melanoma treated with dendritic†…|
L Engell-Noerregaard, E Ellebaek, TZ Iversen, TH Hansen, MK Brimnes, ...
J Clin Cell Immunol 3 (118), 2, 2012
|Immune monitoring using mRNA-transfected dendritic cells|
TH Borch, IM Svane, ÷ Met
Synthetic mRNA, 245-259, 2016